I received a bill last year for a routine MRI of my knee — a twenty-minute scan to evaluate a torn meniscus. The bill was $4,200. My insurance "negotiated" the price down to $2,800. I owed $1,400 after my deductible. When I called the imaging center to ask why the scan cost $4,200, the billing representative could not explain the price. She could tell me what was charged. She could not tell me why.
This is perhaps the most defining feature of the American healthcare system: nobody knows what anything costs, or why. Not the patients, who receive bills weeks or months after services are rendered, in amounts that bear no relationship to the price quoted (if a price was quoted at all). Not the physicians, who order tests and treatments without any mechanism for knowing what those services will cost the patient. Not even the hospitals and health systems, whose pricing is generated by a Byzantine system of cost accounting, charge ratios, and negotiated rates that has evolved over decades into something closer to financial performance art than rational pricing.
The United States spends approximately $4.3 trillion annually on healthcare — 18.3% of GDP, nearly double the OECD average of 9.6% (CMS, 2023). On a per capita basis, the United States spends approximately $12,914 per person per year, compared to $5,882 in Germany, $5,274 in Canada, and $4,653 in the United Kingdom (OECD, 2023). And this extraordinary spending does not produce superior outcomes: the United States ranks last among high-income countries on a comprehensive scorecard of healthcare access, equity, and outcomes compiled by the Commonwealth Fund, with lower life expectancy, higher infant mortality, and higher rates of preventable death than every peer nation studied (Schneider et al., 2021).
We spend more, and get less. Understanding why requires understanding the specific, identifiable mechanisms through which the American system generates extraordinary cost without proportionate value.
Prices, not utilization
The single most important finding in health economics is deceptively simple: the United States does not use more healthcare than other countries. It pays more for the same healthcare. A landmark analysis published in JAMA examined 98 potential drivers of the US spending differential and concluded, with characteristic academic understatement, that "it's the prices, stupid" (Anderson et al., 2003). Updated analyses have consistently confirmed this finding.
American hospital prices are approximately 60% higher than in equivalent European hospitals for identical procedures. American physician salaries are approximately 70% higher than in peer countries. American pharmaceutical prices are approximately 256% higher — the United States is the only developed country that does not negotiate drug prices at the national level, and until the Inflation Reduction Act of 2022, Medicare was explicitly prohibited by law from negotiating prices with pharmaceutical manufacturers.
A hip replacement that costs $10,000-$15,000 in Belgium, France, or the Netherlands costs $28,000-$40,000 in the United States. An MRI that costs $130 in the Netherlands costs $1,100 on average in the US. An angioplasty procedure that costs $6,400 in the Netherlands costs $28,200 in the US (International Federation of Health Plans, 2019). The procedures are identical. The outcomes are comparable. The prices differ by factors of two to five.
The chargemaster system
The mechanism through which hospital prices are generated is the chargemaster — an internal pricing document maintained by every hospital that lists the price of every service, supply, procedure, and item. Chargemasters typically contain 10,000-30,000 line items, from a $37 charge for a single ibuprofen tablet to a $150,000 charge for a cardiac surgery. These prices are set unilaterally by the hospital, are not standardized across institutions, are not publicly disclosed (until recent transparency mandates), and bear no consistent relationship to the cost of providing the service.
Chargemaster prices serve primarily as the starting point for insurance negotiations. Commercial insurers negotiate discounts from chargemaster prices — typically 30-60% — that are specified in contracts and vary by insurer, by hospital, and by service. Medicare and Medicaid pay according to their own fee schedules, which are significantly lower than commercial rates. Uninsured patients, who have no insurer negotiating on their behalf, are technically billed at full chargemaster rates — the highest prices in the system — though many hospitals subsequently offer discounts or charity care.
The result is that the same procedure, performed in the same hospital, by the same physician, costs different amounts depending on who is paying. A study published in Health Affairs found that commercial insurers paid hospitals an average of 247% of Medicare rates for the same services — meaning that privately insured patients effectively subsidize the lower rates paid by government programs (Cooper et al., 2019). This cross-subsidization is both economically inefficient and fundamentally opaque.
Administrative complexity
The American healthcare system spends more on administration than any other country — by a substantial margin. A study published in JAMA estimated that administrative costs accounted for approximately 34.2% of total US healthcare expenditure, compared to 16.7% in Canada — a differential of approximately $812 billion annually (Himmelstein et al., 2020). This administrative overhead finances a vast infrastructure of billing, coding, claims processing, prior authorization, utilization review, credentialing, compliance, and dispute resolution that exists primarily because of the fragmented, multi-payer insurance system.
The United States has approximately 900 private health insurance companies, each with different coverage rules, formularies, networks, prior authorization requirements, and claims processing procedures. Every physician practice must maintain the administrative capacity to interact with all of them — submitting claims in the correct format, with the correct codes, and following up on denials, underpayments, and disputes.
The billing and insurance-related overhead for a typical primary care practice consumes approximately four support staff per physician — compared to approximately 1.5 in Canada and 0.5 in the UK, where single-payer systems dramatically simplify administrative requirements (Woolhandler & Himmelstein, 2014). For every physician practicing medicine in the United States, several additional people are employed to manage the paperwork generated by the payment system.
Prior authorization — the requirement that physicians obtain insurance company approval before providing certain treatments, tests, or medications — represents a particularly costly and clinically harmful form of administrative complexity. A survey by the American Medical Association found that the average physician spends approximately 13 hours per week on prior authorization requirements — roughly two full clinical days — and that 93% of physicians reported care delays due to the prior authorization process (AMA, 2022).
Market consolidation
Healthcare pricing in the United States is theoretically governed by market dynamics — competition between providers should, in theory, drive prices down. In practice, decades of hospital consolidation have created regional monopolies and oligopolies that exercise enormous pricing power.
Since 2000, more than 1,600 hospital mergers have occurred in the United States, reducing competition in most metropolitan areas to a small number of dominant health systems. A comprehensive review published in the Annual Review of Economics analyzed the effects of hospital consolidation and found that mergers consistently increased prices by 20-40% without measurable improvements in quality (Gaynor et al., 2015). When hospitals face less competition, they charge more — because they can, and because the fragmented insurance payment system provides no effective countervailing pressure.
Physician practice consolidation has followed a similar trajectory. Approximately 74% of physicians are now employed by hospitals or large health systems, compared to approximately 40% in 2000 (PAI, 2023). When hospitals acquire physician practices, they can bill for services at hospital outpatient rates rather than office-based rates — even when the service is provided in the same location, by the same physician, to the same patient. This practice, known as "facility fee billing," increases the price of a routine office visit by 100-200% purely through a billing reclassification.
The pharmaceutical pricing problem
The pharmaceutical industry presents the starkest illustration of the pricing dysfunction in American healthcare. The United States is the only large developed country that does not regulate or negotiate pharmaceutical prices at the national level. The consequence is that American patients pay dramatically more for the same medications.
Insulin, a nearly century-old medication essential for the survival of millions of diabetic patients, illustrates the absurdity. The average annual cost of insulin therapy in the United States was approximately $6,000 before recent legislation capped out-of-pocket costs for Medicare beneficiaries at $35 per month — compared to $700-$1,400 in most other developed countries for identical formulations (Bagley et al., 2015). The list price of a vial of Humalog (insulin lispro) increased from $21 in 1999 to $275 in 2019 — a 1,200% increase — without any change in the product, its manufacturing cost, or its clinical efficacy. The sole explanation is pricing power exercised in the absence of regulatory constraint.
The pharmaceutical industry justifies high American prices by arguing that they fund research and development — that American patients are effectively subsidizing the innovation that produces new drugs for the entire world. This argument has some validity: the United States does fund a disproportionate share of pharmaceutical R&D. But the relationship between drug prices and R&D spending is weak. Pharmaceutical companies typically spend more on marketing than on R&D — the industry spent $6.58 billion on direct-to-consumer advertising alone in 2020 (Schwartz & Woloshin, 2019). And the most foundational research underlying new drugs is typically funded by the NIH and academic institutions, not by the pharmaceutical companies that ultimately commercialize and price the products.
The employer-based insurance trap
The employer-sponsored insurance system — which covers approximately 155 million Americans, the single largest source of health coverage — was never designed. It is an accident of World War II-era wage controls, grandfathered into the tax code, and perpetuated by inertia rather than by evidence that it represents an efficient or equitable method of financing healthcare.
The employer-based system creates several structural problems. It ties health coverage to employment, creating gaps for the unemployed, self-employed, part-time workers, and gig economy participants. It distributes the cost of healthcare to employers, who pass these costs through to workers in the form of reduced wages — total compensation stagnation over the past two decades is substantially attributable to rising healthcare costs absorbing earnings growth that would otherwise have gone to wages. And it fragments the risk pool into thousands of employer-based groups, each with different benefits, networks, and cost-sharing structures, preventing the economies of scale and administrative simplification that characterize national systems.
What reform requires
The mechanisms driving American healthcare costs are identifiable, well-documented, and largely amenable to policy intervention. Other countries have solved these problems — not perfectly, but substantially. The solutions include:
All-payer rate setting. Maryland operates the only all-payer rate-setting system in the United States, in which all insurers (including Medicare) pay the same rates for hospital services. The result: Maryland's hospital cost growth has been consistently lower than the national average since the system's implementation, without evidence of quality deterioration. Extending all-payer rate setting nationally would eliminate the cross-subsidization between payer classes and create price discipline.
Administrative simplification. A single-payer system would eliminate the administrative overhead generated by 900 competing insurance companies. Even without single-payer, standardized claims processing, universal prior authorization rules, and interoperable electronic billing systems could reduce administrative spending by hundreds of billions annually.
Drug pricing reform. The Inflation Reduction Act's Medicare negotiation provisions are a start — but they apply only to Medicare, cover only a small number of drugs initially, and do not affect commercial pricing. Comprehensive drug pricing reform requires expanding negotiation authority, establishing international reference pricing, and creating transparency in the pharmaceutical supply chain.
Competition enforcement. Reversing hospital and physician practice consolidation through antitrust enforcement, blocking anti-competitive mergers, and prohibiting facility fee billing for services provided in non-hospital settings would restore the competitive dynamics that are supposed to discipline pricing.
Price transparency. The Hospital Price Transparency Rule, which took effect in 2021, requires hospitals to publish their negotiated rates with all insurers. Compliance has been incomplete and enforcement minimal. Full transparency — combined with consumer-facing tools that allow patients to compare prices before receiving services — is a necessary (though not sufficient) condition for price discipline.
The American healthcare cost crisis is not a natural phenomenon. It is the result of specific policy choices, specific market structures, and specific institutional arrangements that benefit specific stakeholders at the expense of the American public. Other countries have demonstrated that high-quality healthcare can be delivered at half the per-capita cost. The question is not whether reform is possible. It is whether the political will exists to overcome the interests that benefit from the status quo.
My knee MRI cost $4,200. It should not have. The fact that it did — and that no one could explain why — tells you everything you need to know about American healthcare.
References
- AMA. (2022). Prior Authorization Physician Survey. American Medical Association.
- Anderson, G. F., et al. (2003). It's the prices, stupid: Why the United States is so different from other countries. Health Affairs, 22(3), 89–105.
- Bagley, N., et al. (2015). How to fix the high price of drugs. JAMA, 314(17), 1769–1770.
- CMS. (2023). National Health Expenditure Data. Centers for Medicare & Medicaid Services.
- Cooper, Z., et al. (2019). The price ain't right? Hospital prices and health spending on the privately insured. Quarterly Journal of Economics, 134(1), 51–107.
- Gaynor, M., et al. (2015). Making health care markets work: Competition policy for health care. JAMA, 314(14), 1457–1458.
- Himmelstein, D. U., et al. (2020). Health care administrative costs in the United States and Canada, 2017. Annals of Internal Medicine, 172(2), 134–142.
- International Federation of Health Plans. (2019). Comparative Price Report. iFHP.
- OECD. (2023). Health Spending. Organisation for Economic Cooperation and Development.
- PAI. (2023). Physician Employment Trends. Physicians Advocacy Institute.
- Schneider, E. C., et al. (2021). Mirror, Mirror 2021. The Commonwealth Fund.
- Schwartz, L. M., & Woloshin, S. (2019). Medical marketing in the United States, 1997-2016. JAMA, 321(1), 80–96.
- Woolhandler, S., & Himmelstein, D. U. (2014). Administrative work consumes one-sixth of US physicians' working hours. International Journal of Health Services, 44(4), 635–642.